Paid Clinical Trials Dayton

Discover 731 paid clinical trials in Dayton, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 731

LumateperoneMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Recruiting

PHASE3

Sponsor:

Intra-Cellular Therapies, Inc.

Location:

Cincinnati OH, Indianapolis IN, Avon Lake OH, Westlake OHshow 38 more

Code:

NCT06372964

Conditions

Bipolar Depression

Eligibility Criteria

Sex: All

Age: 10 - 17

Healthy Volunteers: Not accepted

Interventions

Lumateperone

Placebo

Suicide Risk ReductionStepped Approach to Reducing Risk of Suicide in Primary Care

Recruiting

Sponsor:

Cynthia Fontanella

Location:

Dayton OH, Kettering OH, Miamisburg OH, Hilliard OHshow 11 more

Code:

NCT06018285

Conditions

Suicidal Ideation

Suicide, Attempted

Suicide Prevention

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Stepped Approach to Reducing Risk of Suicide in Primary Care

Observational StudyCirculating Tumor DNA Exposure in Peripheral Blood

Recruiting

Sponsor:

Quantgene Inc.

Location:

Dayton OH, Centerville OH, Orlando FL, Celebration FLshow 1 more

Code:

NCT03517332

Conditions

Colorectal Cancer

Pancreatic Adenocarcinoma

Gastric Cancer

Hepatocellular Carcinoma

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

IanalumabA Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Dayton OH, Orland Park IL, Duncansville PA, Charlotte NCshow 27 more

Code:

NCT05985915

Conditions

Sjogrens Syndrome

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Ianalumab (VAY736)

Placebo

PovorcitinibA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Recruiting

PHASE3

Sponsor:

Incyte Corporation

Location:

Dayton OH, Dublin OH, Clarksville IN, Troy MIshow 36 more

Code:

NCT06516952

Conditions

Prurigo Nodularis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Povorcitinib

Placebo

Oral & Injectable BuprenorphineA Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

Recruiting

Sponsor:

VA Office of Research and Development

Location:

Dayton OH, Huntington WV, Cleveland OH, Pittsburgh PAshow 20 more

Code:

NCT04375033

Conditions

Opioid Use Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sublingual buprenorphine with naloxone

Injectable subcutaneous buprenorphine

EmpasiprubartA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Recruiting

PHASE2

Sponsor:

argenx

Location:

Dayton OH, Debary FL, Margate FL, Tamarac FLshow 4 more

Code:

NCT06284954

Conditions

Dermatomyositis

Myositis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Empasiprubart IV

Placebo IV

VAX-31A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Recruiting

PHASE2

Sponsor:

Vaxcyte, Inc.

Location:

Dayton OH, Bardstown KY, Cranberry Township PA, Pittsburgh PAshow 19 more

Code:

NCT06720038

Conditions

Pneumococcal Vaccines

Eligibility Criteria

Sex: All

Age: 42 - 70+

Healthy Volunteers: Accepted

Interventions

0.5 mL of the low dose VAX-31

0.5 mL of the mid dose VAX-31

0.5 mL of the high dose VAX-31

0.5 mL dose of PCV20

INDV-6001INDV-6001 Multiple-Dose Pharmacokinetic Study

Recruiting

PHASE2

Sponsor:

Indivior Inc.

Location:

Dayton OH, Chicago IL, Marlton NJ, Staten Island NYshow 7 more

Code:

NCT06576843

Conditions

Moderate to Severe Opioid Use Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

INDV-6001

Suboxone

Sublocade

Neoadjuvant Chemotherapy & TrastuzumabStudy of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting

PHASE2

Sponsor:

NSABP Foundation Inc

Location:

Dayton OH, Columbus OH, Delaware OH, Marion OHshow 33 more

Code:

NCT03412643

Conditions

HER2-negative Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Doxorubicin

Cyclophosphamide

Weekly Paclitaxel

Trastuzumab

Pertuzumab